Sanofi’s new atopic dermatitis therapy accepted for UK early access scheme

Sanofi and its specialty care global business unit Sanofi Genzyme have announced that their new dermatology treatment dupilumab has been accepted for inclusion in a UK early access scheme.

The Medicines and Healthcare Products Regulatory Agency has granted the investigational treatment for atopic dermatitis a positive scientific opinion, meaning it will now be part of the Early Access to Medicines Scheme.

This means that eligible adults with severe forms of the disease will be able to access dupilumab before the drug is granted official marketing authorisation in the UK.

Adult patients whose atopic dermatitis has failed to respond to all currently approved therapies will be able to receive treatment with dupilumab, as well as patients who are intolerant of or ineligible for these existing treatments.

Dr Jasmin Hussein, head of atopic dermatitis and asthma at Sanofi Genzyme for the UK and Ireland, said: "Sanofi is committed to ensuring that people who really need dupilumab have access to it as soon as possible – which is why we applied for EAMS."

Developed in collaboration with Regeneron, dupilumab is currently under review by the European Medicines Agency.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.